Zacks: Analysts Expect Gemphire Therapeutics Inc (GEMP) Will Post Earnings of -$0.42 Per Share

Share on StockTwits

Wall Street brokerages predict that Gemphire Therapeutics Inc (NASDAQ:GEMP) will announce earnings per share of ($0.42) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Gemphire Therapeutics’ earnings. Gemphire Therapeutics reported earnings per share of ($0.58) during the same quarter last year, which suggests a positive year over year growth rate of 27.6%. The firm is scheduled to issue its next earnings report on Tuesday, May 14th.

On average, analysts expect that Gemphire Therapeutics will report full year earnings of ($2.05) per share for the current year, with EPS estimates ranging from ($2.50) to ($1.59). For the next financial year, analysts forecast that the business will report earnings of ($3.55) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Gemphire Therapeutics.

Gemphire Therapeutics (NASDAQ:GEMP) last posted its quarterly earnings results on Friday, March 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15.

Several research firms recently issued reports on GEMP. Zacks Investment Research upgraded Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Friday, March 22nd. ValuEngine cut Gemphire Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Gemphire Therapeutics currently has a consensus rating of “Hold” and an average price target of $14.90.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Gemphire Therapeutics in the 4th quarter worth approximately $27,000. Cary Street Partner Investment Advisory LLC purchased a new stake in Gemphire Therapeutics in the 4th quarter worth approximately $212,000. Finally, BlackRock Inc. lifted its holdings in Gemphire Therapeutics by 2,210.5% in the 3rd quarter. BlackRock Inc. now owns 675,038 shares of the company’s stock worth $1,391,000 after buying an additional 645,822 shares during the period. Institutional investors and hedge funds own 27.17% of the company’s stock.

GEMP opened at $1.27 on Wednesday. Gemphire Therapeutics has a 1 year low of $0.57 and a 1 year high of $11.43. The company has a market cap of $18.12 million, a P/E ratio of -0.74 and a beta of 3.04.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.

Recommended Story: How Do Investors Open a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Gemphire Therapeutics (GEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.